IOVAIovance Biotherapeutics, Inc.

$14.08+529% 1Y

Is it safe?

Watch

Mixed picture: a safe balance sheet and clean books, but quality weak and heavy debt (CCC).

2 good, 3 to watch, 1 without data
SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Honest booksLow risk

Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Quality3 / 9

Weak, deteriorating fundamentals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Credit gradeCCCderived · Jun 30, 2026

Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.

Drawdown risk103% volderived · Oct 23, 2026

Large price swings, high volatility. Worst drawdown -97% · now 5% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitybottom 4% of the market
Max drawdownbottom 4% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can IOVA take a bad year?

The deepest fall in IOVA's price history on file is −97%; it is 5.3% below its high today.

12.81

Altman Z-score · distress below 1.8 · safe above 3 · safe zone, the balance sheet is not what threatens this one

Cash runway
1.0 years

Cash runway · burning $74M a quarter at the current rate

Annualised volatility
103%

Annualised volatility · S&P 500 16% · about 6 times the market's own swing

Worst drawdown on file
−97%

Worst drawdown on file · −5.3% today

Details›
Cash and short-term investments
$298M
EBITDA, trailing twelve months
−$276M
Operating profit, trailing twelve months
−$301M
Annualised volatilitytwo years of daily moves
103%
Worst drawdown on file
−97%
Below its 52-week high
5.3%

Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.

The balance sheet

What it owes against what it owns, and how close that comes to trouble.

How far can it fall?

How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.

On our screens:Most shorted stocks